Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). (Q44522329)

3 December 2017

title

Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). (English)

1 reference

3 December 2017

Laurence Collette

1

1 reference

3 December 2017

Theo M de Reijke

series ordinal

2

1 reference

3 December 2017

Fritz H Schröder

series ordinal

3

1 reference

3 December 2017

EORTC Genito-Urinary Group

series ordinal

4

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

44

1 reference

3 December 2017

issue

2

1 reference

3 December 2017

page(s)

182-9; discussion 189

1 reference

Natural history of progression after PSA elevation following radical prostatectomy

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

What's hot in the prostate?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Prostate-specific antigen and prognosis in patients with metastatic prostate cancer--a multivariable analysis of prostate cancer mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

Follow-up in prostate cancer patients: which parameters are necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900251-3

7 January 2021

10.1016/S0302-2838(03)00251-3

Identifiers

DOI

1 reference

3 December 2017

1 reference